Allergan plc (NYSE:AGN) – Equities researchers at Leerink Swann lifted their Q2 2018 earnings estimates for Allergan in a research report issued to clients and investors on Wednesday. Leerink Swann analyst S. Fernandez now forecasts that the company will earn $3.91 per share for the quarter, up from their previous forecast of $3.79. Leerink Swann currently has a “Outperform” rating and a $242.00 target price on the stock. Leerink Swann also issued estimates for Allergan’s Q4 2018 earnings at $4.10 EPS.

Several other equities analysts also recently commented on AGN. Bank of America increased their price objective on shares of Allergan from $208.00 to $215.00 and gave the company a “buy” rating in a research note on Wednesday. Credit Suisse Group increased their price objective on shares of Allergan from $214.00 to $215.00 and gave the company an “outperform” rating in a research note on Wednesday. Vetr raised shares of Allergan from a “hold” rating to a “buy” rating and set a $189.60 price objective for the company in a research note on Thursday, February 1st. ValuEngine downgraded shares of Allergan from a “buy” rating to a “hold” rating in a research note on Friday, February 2nd. Finally, Cantor Fitzgerald reissued a “hold” rating and issued a $191.00 price objective on shares of Allergan in a research note on Tuesday, February 6th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and fourteen have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $227.23.

Allergan (NYSE AGN) opened at $162.77 on Friday. The company has a market cap of $54,130.00, a P/E ratio of -13.58, a P/E/G ratio of 1.18 and a beta of 1.19. The company has a debt-to-equity ratio of 0.41, a current ratio of 2.04 and a quick ratio of 1.08. Allergan has a 52 week low of $157.70 and a 52 week high of $256.80.

Allergan (NYSE:AGN) last issued its quarterly earnings results on Tuesday, February 6th. The company reported $4.86 earnings per share for the quarter, topping the Zacks’ consensus estimate of $4.74 by $0.12. Allergan had a negative net margin of 26.32% and a positive return on equity of 8.28%. The company had revenue of $4.33 billion during the quarter, compared to the consensus estimate of $4.28 billion. During the same quarter in the prior year, the firm posted $3.90 EPS. The firm’s quarterly revenue was up 12.0% on a year-over-year basis.

Several hedge funds have recently added to or reduced their stakes in the company. Cable Hill Partners LLC increased its position in shares of Allergan by 255.2% during the third quarter. Cable Hill Partners LLC now owns 515 shares of the company’s stock worth $106,000 after buying an additional 370 shares during the period. Rockefeller Financial Services Inc. increased its position in shares of Allergan by 283.7% during the third quarter. Rockefeller Financial Services Inc. now owns 541 shares of the company’s stock worth $111,000 after buying an additional 400 shares during the period. BB&T Investment Services Inc. increased its position in shares of Allergan by 1,308.2% during the third quarter. BB&T Investment Services Inc. now owns 690 shares of the company’s stock worth $139,000 after buying an additional 641 shares during the period. Phocas Financial Corp. acquired a new stake in shares of Allergan during the second quarter worth $150,000. Finally, Acropolis Investment Management LLC acquired a new stake in shares of Allergan during the fourth quarter worth $153,000. 80.23% of the stock is owned by hedge funds and other institutional investors.

In other Allergan news, Chairman Brent L. Saunders purchased 4,600 shares of the company’s stock in a transaction dated Wednesday, December 6th. The stock was purchased at an average price of $164.74 per share, with a total value of $757,804.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Chris W. Bodine purchased 3,030 shares of the company’s stock in a transaction dated Thursday, December 7th. The shares were acquired at an average cost of $164.77 per share, with a total value of $499,253.10. The disclosure for this purchase can be found here. Insiders have bought 17,630 shares of company stock valued at $2,890,057 in the last ninety days. Insiders own 0.36% of the company’s stock.

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, March 28th. Stockholders of record on Wednesday, February 28th will be paid a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a dividend yield of 1.77%. This is an increase from Allergan’s previous quarterly dividend of $0.70. Allergan’s dividend payout ratio (DPR) is presently -23.35%.

ILLEGAL ACTIVITY NOTICE: “Leerink Swann Equities Analysts Raise Earnings Estimates for Allergan plc (AGN)” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another website, it was stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this story can be read at https://www.thecerbatgem.com/2018/02/11/leerink-swann-equities-analysts-raise-earnings-estimates-for-allergan-plc-agn.html.

Allergan Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Earnings History and Estimates for Allergan (NYSE:AGN)

Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.